Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Intra-Cellular Ther
(NQ:
ITCI
)
69.72
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
69.72
Bid (Size)
65.00 (1)
Ask (Size)
74.00 (1)
Prev. Close
69.72
Today's Range
69.72 - 69.72
52wk Range
45.50 - 76.11
Shares Outstanding
94,324,313
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Where Intra-Cellular Therapies Stands With Analysts
February 23, 2024
Via
Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
February 21, 2024
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.
Via
InvestorPlace
Performance
YTD
-1.09%
-1.09%
1 Month
-2.57%
-2.57%
3 Month
-5.34%
-5.34%
6 Month
+28.82%
+28.82%
1 Year
+25.10%
+25.10%
More News
Read More
Analyst Scoreboard: 8 Ratings For Intra-Cellular Therapies
January 18, 2024
Via
Benzinga
In-Depth Examination Of 6 Analyst Recommendations For Intra-Cellular Therapies
January 02, 2024
Via
Benzinga
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
December 29, 2023
Via
MarketBeat
10 Health Care Stocks Whale Activity In Today's Session
December 14, 2023
Via
Benzinga
Expert Ratings for Intra-Cellular Therapies
December 11, 2023
Via
Benzinga
Intra-Cellular Therapies's Earnings: A Preview
November 01, 2023
Via
Benzinga
What 10 Analyst Ratings Have To Say About Intra-Cellular Therapies
August 22, 2023
Via
Benzinga
Are These Biotechs Ready To Launch?
December 09, 2023
Via
Talk Markets
Analyst Expectations for Intra-Cellular Therapies's Future
August 03, 2023
Via
Benzinga
Intra-Cellular Therapies Better Positioned For Success: Analyst Anticipates Positive Phase 3 Depression Trial Data
July 06, 2023
Via
Benzinga
Needham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To Know
July 06, 2023
Via
Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
June 22, 2023
Via
Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
June 05, 2023
Via
Benzinga
Recap: Intra-Cellular Therapies Q1 Earnings
May 04, 2023
Via
Benzinga
A Preview Of Intra-Cellular Therapies's Earnings
May 03, 2023
Via
Benzinga
Analyst Ratings for Intra-Cellular Therapies
March 29, 2023
Via
Benzinga
Intra-Cellular Stock Surges As Antipsychotic Shows Benefit In Depression Patients With Mixed Features
March 28, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023
April 20, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
April 07, 2023
Via
Benzinga
Airbnb To Rally Around 59%? Here Are 10 Other Analyst Forecasts For Wednesday
March 29, 2023
Via
Benzinga
Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 28, 2023
Via
Benzinga
Why Intra-Cellular Therapies Climbed Tuesday
March 28, 2023
Via
The Motley Fool
Intra-Cellular's Big Depression Drug Market Just Got Bigger — And Shares Catapulted
March 28, 2023
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.